Skip to content
value.today

Thermalin Diabetes, LLC

🇺🇸 Cleveland, Ohio, USABiotechnologyFounded 2010
Total raised
$12 M
3 rounds on record
Latest round
$7 M
Jun 2013
First round on record
Oct 2010
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Thermalin Diabetes, LLC
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2013$7 MNo. 3$2 to $10 million

Thermalin Diabetes, LLC: Raise no. 3, Jun 2013

Investors in this round

71 investors had bought by the notice of Jul 28, 2014: 71 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $14 M offered; $7 M still to sell
Smallest investment taken
$100,000
What was sold
equity, other: Series B Preferred Shares. The minumum amount reflected in Item 11 may be waived by the Issuer.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • Bruce H. Frank · Executive Officer · Dr, Frank is the Vice President of Development.
  • Michael Weiss · Executive Officer, Director, Promoter · Dr. Weiss is the founder and chief scientific officer of the Issuer
  • Richard Berenson · Executive Officer, Director, Promoter · Mr. Berenson is a founder and the Chief Executive Officer of the Issuer.
  • Gerald Wisler · Director
  • Jeffrey Elton · Director
  • John Brooks · Director
  • Raymond Rackley · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Richard Berenson, Chief Executive Officer of the Issuer. Newest notice filed Jul 28, 2014 (1 amendment). Read the notice at the SEC.

equitySEC
May 2012$3 MNo. 2$2 to $10 million

Thermalin Diabetes, LLC: Raise no. 2, May 2012

Investors in this round

33 investors had bought by the notice of Sep 3, 2013: 33 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities, securities to be acquired by exercising them, other: Promissiory notes with common stock purchase warrants. The notes can be converted into preferred stock subject to certain conditions.
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • Michael Weiss · Executive Officer, Director, Promoter · Dr. Weiss is the founder and chief scientific officer of the Issuer
  • Mitchell Briskin · Executive Officer · Mr. Briskin is the Vice President of Strategic Relationships.
  • Richard Berenson · Executive Officer, Director, Promoter · Mr. Berenson is a founder and the Chief Executive Officer of the Issuer.
  • Jeffrey Elton · Director
  • John Brooks · Director
  • Joseph Jankowski · Director
  • Raymond Rackley · Director
  • Steven Tregay · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Represents total amount of promissory notes without any interest.”

Signed by Richard Berenson, Chief Executive Officer of the Issuer. Newest notice filed Sep 3, 2013. Read the notice at the SEC.

equity, debt, optionsSEC
Oct 2010$3 MNo. 1$2 to $10 million

Thermalin Diabetes, LLC: Raise no. 1, Oct 2010

Investors in this round

37 investors had bought by the notice of Mar 29, 2011: 37 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
$135,233 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • Richard Berenson · Executive Officer, Director
  • John Brooks · Director
  • Michael Weiss · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Approximately $431,000 of the Total Amount Sold represents the conversion of certain debt into the equity sold hereunder.”
  • On the use of proceeds: “Approximately $135,233 has been paid to Venzyme Catalyst, LLC for outstanding consulting fees. Richard Berenson (the president and a manager of Thermalin Diabetes, LLC) is the managing director of Venzyme Catalyst, LLC.”

Signed by Richard Berenson, Chief Executive Officer. Newest notice filed Mar 29, 2011 (2 amendments). Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Thermalin Diabetes, LLC chose not to state its revenue in its newest notice of a funding round (Jul 2014).

    SEC Form D · Jul 2014

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2014

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Thermalin Diabetes, LLC is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Thermalin Diabetes, LLC
NameRoleNamed in
Bruce H. FrankDr, Frank is the Vice President of Development.Jul 2014
Michael WeissDr. Weiss is the founder and chief scientific officer of the IssuerJul 2014
Richard BerensonMr. Berenson is a founder and the Chief Executive Officer of the Issuer.Jul 2014
Mitchell BriskinMr. Briskin is the Vice President of Strategic Relationships.Sep 2013
Gerald WislerDirectorJul 2014
Jeffrey EltonDirectorJul 2014
John BrooksDirectorJul 2014
Michael WeissDr. Weiss is the founder and chief scientific officer of the IssuerJul 2014
Raymond RackleyDirectorJul 2014
Richard BerensonMr. Berenson is a founder and the Chief Executive Officer of the Issuer.Jul 2014
Joseph JankowskiDirectorSep 2013
Steven TregayDirectorSep 2013
Michael WeissDr. Weiss is the founder and chief scientific officer of the IssuerJul 2014
Richard BerensonMr. Berenson is a founder and the Chief Executive Officer of the Issuer.Jul 2014